Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amy Dréan"'
Autor:
Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I. Harrell, Malini Menon, Rachel Brough, James Campbell, Jessica Frankum, Michael Ranes, Helen N. Pemberton, Rumana Rafiq, Kerry Fenwick, Amanda Swain, Sebastian Guettler, Jung-Min Lee, Elizabeth M. Swisher, Stoyno Stoynov, Kosuke Yusa, Alan Ashworth, Christopher J. Lord
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
The mechanisms of PARP inhibitor (PARPi) resistance are poorly understood. Here the authors employ a CRISPR mutagenesis approach to identify PARP1 mutants causing PARPi resistance and find that PARP1 mutations are tolerated in BRCA1 mutated cells, su
Externí odkaz:
https://doaj.org/article/1eb977c74fb546b0a7321e49be5d0643
Autor:
Christopher J. Lord, Alan Ashworth, Stephen J. Pettitt, Nicholas C. Turner, Aditi Gulati, James Campbell, Nicholas Badham, Rumana Rafiq, Jessica Frankum, Helen N. Pemberton, Isaac Garcia-Murillas, Asha Konde, Malini Menon, Inger Brandsma, Rachel Brough, Chris T. Williamson, Amy Dréan
Figure S1: Characterisation of CAPAN1-B2S* Figure S2: Characterisation of SUM149-B1S* Figure S3: Sensitivity of ddPCR assay. Figure S4: Olaparib and talazoparib select for secondary mutant tumour cells. Figure S5: DLD1 tumour cells have a fitness adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c87fbc8e38f13dde6b24d9910847b29
https://doi.org/10.1158/1535-7163.22508823.v1
https://doi.org/10.1158/1535-7163.22508823.v1
Autor:
Christopher J. Lord, Alan Ashworth, Stephen J. Pettitt, Nicholas C. Turner, Aditi Gulati, James Campbell, Nicholas Badham, Rumana Rafiq, Jessica Frankum, Helen N. Pemberton, Isaac Garcia-Murillas, Asha Konde, Malini Menon, Inger Brandsma, Rachel Brough, Chris T. Williamson, Amy Dréan
ddPCR probe and primer design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761be8a75a4e995d41eba19da335de90
https://doi.org/10.1158/1535-7163.22508817.v1
https://doi.org/10.1158/1535-7163.22508817.v1
Autor:
Sebastian Guettler, Amanda Swain, Rachel Brough, Inger Brandsma, Helen Pemberton, Kerry Fenwick, Michael Ranes, Radoslav Aleksandrov, Stephen J. Pettitt, James Campbell, Malini Menon, Alan Ashworth, Jung-Min Lee, Maria I. Harrell, Kosuke Yusa, Dragomir B. Krastev, Amy Dréan, Elizabeth M. Swisher, Feifei Song, Stoyno S. Stoynov, Jessica Frankum, Christopher J. Lord, Rumana Rafiq
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Nature Communications
Nature Communications
Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 “tag-mutate-enrich” mutagenesis s
Autor:
Asha Konde, Malini Menon, Inger Brandsma, Helen Pemberton, James Campbell, Alan Ashworth, Chris T. Williamson, Rachel Brough, Amy Dréan, Christopher J. Lord, Nicholas Badham, Nicholas C. Turner, Rumana Rafiq, Isaac Garcia-Murillas, Aditi Gulati, Jessica Frankum, Stephen J. Pettitt
Publikováno v:
Molecular Cancer Therapeutics. 16:2022-2034
Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutan
Publikováno v:
Critical Reviews in Oncology/Hematology. 108:73-85
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppress
Autor:
Amy, Dréan, Chris T, Williamson, Rachel, Brough, Inger, Brandsma, Malini, Menon, Asha, Konde, Isaac, Garcia-Murillas, Helen N, Pemberton, Jessica, Frankum, Rumana, Rafiq, Nicholas, Badham, James, Campbell, Aditi, Gulati, Nicholas C, Turner, Stephen J, Pettitt, Alan, Ashworth, Christopher J, Lord
Publikováno v:
Molecular cancer therapeutics. 16(9)
Although PARP inhibitors target BRCA1 or BRCA2 mutant tumour cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutan